Raptor Pharmaceutical Corp. (RPTP), AVEO Pharmaceuticals, Inc. (AVEO) & Two FDA Decisions You Can’t Afford to Miss This Week

Regardless of what the FDA panel has to say about Tivozanib, it could be an uphill struggle given that seven drugs are currently approved by the FDA to treat renal cell carcinoma. In addition to the aforementioned Nexavar, Pfizer Inc. (NYSE:PFE)‘s Sutent is a lead drug in metastatic renal cell carcinoma, delivering $1.24 billion in sales — a 9% year-over-year increase — in 2012.Even if Tivozanib makes it through the gauntlet, it could have a hard time swaying physicians away from these two commonly prescribed medications.

The article 2 FDA Decisions You Can’t Afford to Miss This Week originally appeared on Fool.com and is written by Sean Williams.

Fool contributor Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.